Stock Events

Orexo AB 

$2.21
2
+$0+0% Friday 13:53

Statistics

Day High
1.65
Day Low
1.65
52W High
1.65
52W Low
0.76
Volume
257
Avg. Volume
72
Mkt Cap
77.75M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

2NovConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-2.15
-1.5
-0.85
-0.2
Expected EPS
-1.68
Actual EPS
-0.77

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ORXOY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Pharmaceuticals: Other
Health Technology
Manufacturing
Medicinal and Botanical Manufacturing
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Show more...
CEO
Nikolaj Soerensen
Employees
113
Country
US
ISIN
US68616W1027

Listings